ChemicalBook--->CAS DataBase List--->153814-74-5

153814-74-5

153814-74-5 Structure

153814-74-5 Structure
IdentificationBack Directory
[Name]

Acetic acid, [[7,8-dihydro-5-[2-[[(Z)-(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]-1-naphthalenyl]oxy]- (9CI)
[CAS]

153814-74-5
[Synonyms]

Acetic acid, [[7,8-dihydro-5-[2-[[(Z)-(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]-1-naphthalenyl]oxy]- (9CI)
[Molecular Formula]

C26H24N2O4
[MOL File]

153814-74-5.mol
[Molecular Weight]

428.48
Chemical PropertiesBack Directory
[Boiling point ]

635.7±65.0 °C(Predicted)
[density ]

1.21±0.1 g/cm3(Predicted)
[form ]

Solid
[pka]

3.17±0.10(Predicted)
[color ]

Off-white to light yellow
Hazard InformationBack Directory
[Uses]

(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].
[References]

[1] Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699(1-3):81-87. DOI:10.1016/j.ejphar.2012.11.045
[2] Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269-278. DOI:10.1124/jpet.115.222612
[3] Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2018;43(11):E616-E624. DOI:10.1097/BRS.0000000000002439
153814-74-5 suppliers list
Tags:153814-74-5 Related Product Information
26441-05-4 155206-00-1 53902-12-8 415903-37-6 130209-82-4 1154-25-2